- Molecular NameTranexamic_acid
- SynonymTranexamsaeure; tranexmic acid; Tranhexamic acid; Trans AMCHA; trans-4-aminomethylcyclohexane-1-carboxylic acid; trans-Amcha; trans-Tranexamic acid
- Weight157.213
- Drugbank_IDDB00302
- ACS_NO1197-18-8
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)-1.68
- pkaN/A
- LogD (pH=7, predicted)-4.18
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-0.13
- LogSw (predicted, AB/LogsW2.0)53.82
- Sw (mg/ml) (predicted, ACD/Labs)115.8
- No.of HBond Donors3
- No.of HBond Acceptors3
- No.of Rotatable Bonds2
- TPSA63.32
- StatusFDA approved
- AdministrationInjection and oral
- PharmacologyAn antifibrinolytic that competitively inhibits the activation of plasminogen to plasmin, a molecule responsible for the degradation of fibrin.
- Absorption_value55.0
- Absorption (description)Absorption of tranexamic acid after oral administration in humans represents approximately 30 to 50% of the ingested dose and bioavailability is not affected by food intake.
- Caco_2N/A
- Bioavailability34.0
- Protein binding3.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmOnly a small fraction of the drug is metabolized (less than 5%).
- Half life3.1 h
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityOral LD50 in mice is >10 gm/kg. Symptoms of overdosage may be nausea, vomiting, orthostatic symptoms and/or hypotension.
- LD50 (rat)N/A
- LD50 (mouse)N/A